Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0873 in Rheumatoid Arthritis
NCT00132769Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0873 in rheumatoid arthritis (RA), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Swollen Joint Count at 12 weeks. Started Jan 2005; status: completed.
02
Drugs
MK-0873
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00132769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132769.